Abstract:
Objective
To investigate the expression change of CK19 in breast cancer patients after neoadjuvant chemotherapy and its clinical significance.
Methods
Using real-time quantitative RT-PCR (qRT-PCR), CK19 mRNA expression in peripheral blood of 86 patients with breast cancer were detected before and after neoadjuvant chemotherapy, with 20 healthy individuals and 24 patients with benign breast lesions as controls. The data with non-normal distribution or heterogeneity of variance were processed using Wilcoxon nonparametric rank sum test, expressed as M(QR).χ2 test was performed for numeration data.
Results
The positive rate of CK19 mRNA in peripheral blood before neoadjuvant chemotherapy was 32.56%(28/86), which showed a correlation with lymphatic metastasis and clinical stages(P<0.001). But it decreased to 13.95% (12/86) after neoadjuvant chemotherapy, which was significantly lower than that before neoadjuvant chemotherapy (P=0.004). After neoadjuvant chemotherapy, 57.14%of the patients(16/28)with CK19 mRNA positive expression showed complete or partial remission, significantly lower than 93.10% (54/58)in the patients with CK19 mRNA negative expression(P<0.001), which suggested that the change of CK19 mRNA expression may correlate with neoadjuvant chemotherapy response.
Conclusion
CK19 can be used as an early predictor of neoadjuvant chemotherapy efficacy.
Key words:
breast neoplasms,
neoadjuvant chemotherapy,
cytokeratin 19,
qRTPCR
Ying MAO, Tianning ZOU, Zhuang-qing YANG, Ji ZHANG. Change of CK19 expression in peripheral blood of breast cancer patients before and after neoadjuvant chemotherapy and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2012, 06(04): 394-401.